

## INOVIQ CSO RECEIVES PLACENTOLOGY SCIENTIFIC AWARD

INOVIQ is pleased to announce that Chief Scientific Officer, Professor Greg Rice, has been awarded the prestigious *Joan Hunt IFPA Senior Award in Placentology for 2023*.

This award represents the highest distinction of the international placental research community, and recognises the work of established senior scientists/PIs/clinicians who have made a significant contribution to the understanding of placental and reproductive functions in general.

Professor Greg Rice is an internationally recognised academic and commercial scientist with more than 30 years' experience in oncology, perinatology, exosome-based research and clinical translational research. He has been instrumental in driving research around the use of exosomes in obstetrical medicine and diagnostics. Prof Rice recently presented on the topic of "Enabling EV-based Biomarker Discovery and Diagnostics" at the Preterm Birth International Collaborative (PREBIC) Australasian Workshop. You can access a copy of this presentation [here](#).

For further information about the International Federation of Placenta Associations (IFPA) and the IFPA Award in Placentology, please visit [here](#).

### COMPANY CONTACTS

**Dr Leearne Hinch**  
Chief Executive Officer  
E [lhinch@inoviq.com](mailto:lhinch@inoviq.com)  
M +61 400 414 416

**Dr Geoff Cumming**  
Non-Executive Chairman  
E [geoff.cumming@inoviq.com](mailto:geoff.cumming@inoviq.com)  
M +61 417 203 021

**Jane Lowe**  
IR Department  
E [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)  
M +61 411 117 774

### ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising next-generation exosome capture tools and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the EXO-NET pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers. For more information on INOVIQ, see [www.inoviq.com](http://www.inoviq.com).